

# Network-based Drug Repurposing for Human Coronavirus

Yadi Zhou<sup>1,#</sup>, Yuan Hou<sup>1,#</sup>, Jiayu Shen<sup>1</sup>, Yin Huang<sup>1</sup>, William Martin<sup>1</sup>, Feixiong Cheng<sup>1-3,\*</sup>

<sup>1</sup>Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA

<sup>2</sup>Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA

<sup>3</sup>Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Oh 44106, USA

#Equal contribution

\*Correspondence to:

Feixiong Cheng, PhD

Lerner Research Institute

Cleveland Clinic

Tel: +1-216-444-7654; Fax: +1-216-636-0009

Email: [chengf@ccf.org](mailto:chengf@ccf.org)

## Abstract

Human Coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle east respiratory syndrome coronavirus (MERS-CoV), and 2019 novel coronavirus (2019-nCoV), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV. Drug repurposing, represented as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to *de novo* drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV-host interactome and drug targets in the human protein-protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV has the highest nucleotide sequence identity with SARS-CoV (79.7%) among the six other known pathogenic HCoVs. Specifically, the envelope and nucleocapsid proteins of 2019-nCoV are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and known HCoV-host interactions in the human protein-protein interactome, we computationally identified 135 putative repurposable drugs for the potential prevention and treatment of HCoVs. In addition, we prioritized 16 potential anti-HCoV repurposable drugs (including melatonin, mercaptopurine, and sirolimus) that were further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. Finally, we showcased three potential drug combinations (including sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by

the ‘*Complementary Exposure*’ pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human protein-protein interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations toward future clinical trials for HCoVs.

## Introduction

Coronaviruses (CoVs) typically affect the respiratory tract of mammals, including humans, and lead to mild to severe respiratory tract infections<sup>[1]</sup>. In the past 2 decades, two highly pathogenic human CoVs (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), emerging from animal reservoirs, have led to global epidemics with high morbidity and mortality<sup>[2]</sup>. For example, 8,098 individuals were infected and 774 died in the SARS-CoV pandemic, which cost the global economy with an estimated \$30 to \$100 billion<sup>[3, 4]</sup>. According to the World Health Organization (WHO), as of November 2019, MERS-CoV has had a total of 2,494 diagnosed cases causing 858 deaths, the majority in Saudi Arabia<sup>[2]</sup>. In December 2019, the third pathogenic HCoV, named 2019 novel coronavirus (2019-nCoV), was found in Wuhan, China. As of February 02, 2020, there have been over 14,000 cases with ~300 deaths for the 2019-nCoV pandemic (<https://www.cdc.gov/coronavirus/2019-ncov/index.html>); furthermore, human-to-human transmission has occurred among close contacts<sup>[5]</sup>. However, there are currently no effective medications against 2019-nCoV. Several national and international research

groups are working on the development of vaccines to prevent and treat the 2019-nCoV, but effective vaccines are not available yet. There is an urgent need for the development of effective prevention and treatment strategies for 2019-nCoV outbreak.

Although investment in biomedical and pharmaceutical research and development has increased significantly over the past two decades, the annual number of new treatments approved by the U.S. Food and Drug Administration (FDA) has remained relatively constant and limited<sup>[6]</sup>. A recent study estimated that pharmaceutical companies spent \$2.6 billion in 2015, up from \$802 million in 2003, in the development of an FDA-approved new chemical entity drug<sup>[7]</sup>. Drug repurposing, represented as an effective drug discovery strategy from existing drugs, could significantly shorten the time and reduce the cost compared to *de novo* drug discovery and randomized clinical trials<sup>[8-10]</sup>. However, experimental approaches for drug repurposing is costly and time-consuming.<sup>[11]</sup> Computational approaches offer novel testable hypotheses for systematic drug repositioning<sup>[8-10, 12, 13]</sup>. However, traditional structure-based methods are limited when three-dimensional (3D) structures of proteins are unavailable, which, unfortunately, is the case for the majority of human and viral targets. In addition, targeting single virus proteins often have high risk of drug resistance by the rapid evolution of virus genomes<sup>[1]</sup>.

Viruses (including HCoV) require host cellular factors for successful replication during infections<sup>[1]</sup>. Systematic identification of virus-host protein-protein interactions (PPIs) offers an effective way toward elucidation of the mechanisms of viral infection<sup>[14, 15]</sup>. Subsequently, targeting cellular antiviral targets, such as virus-host interactome, may offer a novel strategy for the development of effective treatments for viral

infections<sup>[1]</sup>, including SARS-CoV<sup>[16]</sup>, MERS-CoV<sup>[16]</sup>, Ebola virus<sup>[17]</sup>, and Zika virus<sup>[13, 18-20]</sup>. We recently presented an integrated antiviral drug discovery pipeline that incorporated gene-trap insertional mutagenesis, known functional drug-gene network, and bioinformatics analyses<sup>[13]</sup>. This methodology allows to identify several candidate repurposable drugs for Ebola virus<sup>[10, 13]</sup>. Our work over the last decade has demonstrated how network strategies can, for example, be used to identify effective repurposable drugs<sup>[12, 21-24]</sup> and drug combinations<sup>[25]</sup> for multiple human diseases. For example, network-based drug-disease proximity that sheds light on the relationship between drugs (e.g., drug targets) and disease modules (molecular determinants in disease pathobiology modules within the PPIs), and can serve as a useful tool for efficient screening of potentially new indications for approved drugs, as well as drug combinations, as demonstrated in our recent studies<sup>[12, 22, 25]</sup>.

In this study, we present an integrative, antiviral drug repurposing methodology that combines a systems pharmacology-based network medicine platform that quantifies the interplay between the virus-host interactome and drug targets in the human PPI network. The basis for these experiments rests on the notions that (i) the proteins that functionally associate with viral infection (including HCoV) are localized in the corresponding subnetwork within the comprehensive human PPI network<sup>[26]</sup>; and (ii) proteins that serve as drug targets for a specific disease may also be suitable drug targets for potential antiviral infection owing to common PPIs and functional pathways elucidated by the human interactome (**Figure 1**). We follow this analysis with bioinformatics validation of drug-induced gene signatures and HCoV-induced

transcriptomics in human cell lines to inspect the postulated mechanism-of-action in a specific HCoV for which we propose repurposing (**Figure 1**).

## Results

### Phylogenetic Analyses of 2019-nCoV

To date, 7 pathogenic HCoVs (**Figure 2A** and **2B**) have been found<sup>[1, 27]</sup>: (i) 2019-nCoV, SARS-CoV, MERS-CoV, HCoV-OC43, and HCoV-HKU1 are  $\beta$  genera, and (ii) HCoV-NL63 and HCoV-229E are  $\alpha$  genera. We performed the phylogenetic analyses using the whole genome sequence data from 15 HCoVs to inspect the evolutionary relationship of 2019-nCoV with other HCoVs. We found that the whole genomes of 2019-nCoV had ~99.99% nucleotide sequence identity across three diagnosed patients (Supplementary **Table S1**). The 2019-nCoV shares the highest nucleotide sequence identity (79.7%) with SARS-CoV among the 6 other known pathogenic HCoVs, revealing conserved evolutionary relationship between 2019-nCoV and SARS-CoV (**Figure 2A**).

HCoVs have five major protein regions for virus structure assembly and viral replications<sup>[27]</sup>, including replicase complex (ORF1ab), spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins (**Figure 2B**). The ORF1ab gene encodes the non-structural proteins (nsp) of viral RNA synthesis complex through proteolytic processing<sup>[28]</sup>. The nsp12 is a viral RNA-dependent RNA polymerase, together with co-factors nsp7 and nsp8 possessing high polymerase activity. From the protein three-dimensional (3D) structure view of SARS-CoV nsp12, it contains a larger N-terminal extension (which binds to nsp7 and nsp8) and polymerase domain (**Figure 2C**). The

spike is a transmembrane glycoprotein that plays a pivotal role in mediating viral infection through binding the host receptor<sup>[29, 30]</sup>. **Figure 2D** shows the 3D structure of the spike protein bound with the host receptor angiotensin converting enzyme2 (ACE2) in SARS-CoV (PDB ID: 6ACK). A recent study showed that 2019-nCoV is able to utilize ACE2 as an entry receptor in ACE2-expressing cells<sup>[31]</sup>, suggesting potential drug targets for therapeutic development. In addition, the nucleocapsid is also an important subunit for packaging the viral genome through protein oligomerization<sup>[32]</sup>, and the single nucleocapsid structure was shown in **Figure 2E**.

Protein sequence alignment analyses indicated that the 2019-nCoV was most evolutionarily conserved with SARS-CoV (Supplementary **Table S2**). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV are two evolutionarily conserved regions, with sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV (Supplementary **Table S2**). However, the spike protein exhibited the lowest sequence conservation (sequence identity of 77%) between 2019-nCoV and SARS-CoV. Meanwhile, the spike protein of 2019-nCoV only has 31.9% sequence identity compared to MERS-CoV.

### **HCoV-host Interactome Network**

First, we assembled the CoV-associated host proteins from 4 known HCoVs (SARS-CoV, MERS-CoV, HCoV-229E, and HCoV-NL63), one mouse MHV, and one avian IBV (N protein) (Supplementary **Table S3**). In total, we obtained 119 host proteins associated with CoVs with various experimental evidences. Specifically, these host

proteins are either the direct targets of HCoV proteins or are involved in crucial pathways of HCoV infection. The HCoV-host interactome network is shown in **Figure 3A**. We identified several hub proteins including JUN, XPO1, NPM1, and HNRNPA1, with the highest number of connections within the 119 proteins. KEGG pathway enrichment analysis revealed multiple significant biological pathways (adjusted  $P$  value  $< 0.05$ ), including measles, RNA transport, NF-kappa B signaling, Epstein-Barr virus infection, and influenza (**Figure 3B**). Gene ontology (GO) biological process enrichment analyses further confirmed multiple viral infection-related processes (adjusted  $P$  value  $< 0.001$ ), including viral life cycle, modulation by virus of host morphology or physiology, viral process, positive regulation of viral life cycle, transport of virus, and virion attachment to host cell (**Figure 3C**). We then mapped the known drug-target network (see **Methods**) into the HCoV-host interactome to search for druggable, cellular targets. We found that 47 human proteins (39%, blue nodes in **Figure 3A**) can be targeted by at least one approved drug or experimental drug under clinical trial. For example, GSK3B, DPP4, SMAD3, PARP1, and IKBKB are the most targetable proteins. The high druggability of HCoV-host interactome motivates us to develop a therapeutic strategy by specifically targeting cellular proteins associated with HCoVs, such as drug repurposing.

### Network-based Drug Repurposing for HCoVs

The basis for the proposed network-based drug repurposing methodologies rests on the notions that the proteins that associate with and functionally govern a viral infection are localized in the corresponding subnetwork (**Figure 1A**) within the comprehensive human interactome network. For a drug with multiple targets to be effective against an



HCoV, its target proteins should be within or in the immediate vicinity of the corresponding subnetwork in the human interactome (**Figure 1**), as we demonstrated in multiple diseases [12, 21, 22, 25] using this drug repurposing strategy. We used a state-of-the-art network proximity measure to quantify the relationship between HCoV-specific subnetwork (**Figure 3A**) and drug targets in the human protein-protein interactome. We constructed a drug-target network by assembling target information for more than 2,000 FDA-approved or experimental drugs (see **Methods**). To improve the quality and completeness of the human protein interactome network, we integrated PPIs with five types of experimental data: (1) binary PPIs from 3D protein structures; (2) binary PPIs from unbiased high-throughput yeast-two-hybrid assays; (3) experimentally identified kinase-substrate interactions; (4) signaling networks derived from experimental data; and (5) literature-derived PPIs with various experimental evidences (see **Methods**). We used a Z-score (Z) measure and permutation test to reduce the study bias in network proximity analyses (including hub nodes in the human interactome network by literature-derived PPI data bias) as described in our recent studies<sup>[12, 25]</sup>.

In total, we computationally identified 135 drugs that were associated ( $Z < -1.5$  and  $P < 0.05$ , permutation test) with the HCoV-host interactome (**Figure 4A** and Supplementary **Table S4**). To validate bias of the pooled cellular proteins from 6 CoVs, we further calculated the network proximities of all the drugs for 4 CoVs with a high enough number of known host proteins, including SARS-CoV, MERS-CoV, IBV, and MHV, separately. We found that the Z-scores showed consistency among the pooled 119 HCoV-associated proteins and other 4 individual CoVs (**Figure 4B**). The Pearson correlation coefficients of the proximities of all the drugs for the pooled HCoV are 0.926

vs. SARS-CoV ( $P < 0.001$ ,  $t$  distribution), 0.503 vs. MERS-CoV ( $P < 0.001$ ), 0.694 vs. IBV ( $P < 0.001$ ), and 0.829 vs. MHV ( $P < 0.001$ ). These network proximity analyses offer putative repurposable candidates for potential prevention and treatment of HCoVs.

## Discovery of Repurposable Drugs for HCoV

To further validate the 135 repurposable drugs against HCoVs, we first performed gene set enrichment analysis (GSEA) using transcriptome data of MERS-CoV and SARS-CoV infected host cells (see **Methods**). These transcriptome data were used as gene signatures for HCoVs. Additionally, we downloaded the expression data of drug-treated human cell lines from the Connectivity Map (CMAP) database <sup>[33]</sup> to obtain drug-gene signatures. We calculated a GSEA score (see **Methods**) for each drug and used this score as an indication of bioinformatics validation of the 135 drugs. Specifically, an enrichment score ( $ES$ ) was calculated for each HCoV data set, and  $ES > 0$  and  $P < 0.05$  (permutation test) was used as cut-off for a significant association of gene signatures between a drug and a specific HCoV. The GSEA score, ranging from 0 to 3, is the number of data sets that met these criteria for a specific drug. Mesalazine (an approved drug for inflammatory bowel disease), sirolimus (an approved immunosuppressive drug), and equilin (an approved agonist of the estrogen receptor for menopausal symptoms) achieved the highest GSEA scores of 3, followed by paroxetine and melatonin with GSEA scores of 2. We next selected 16 potential repurposable drugs (**Figure 5A** and **Table 1**) against HCoVs using subject matter expertise based on a combination of factors: (i) strength of the network-predicted associations (a smaller network proximity score in Supplementary **Table S4**); (ii) validation by GSEA analyses;

(iii) literature-reported antiviral evidences, and (iv) fewer clinically reported side effects. Specifically, we showcased several selected repurposable drugs with literature-reported antiviral evidences as below.

**Selective estrogen receptor modulators (SERMs).** An overexpression of estrogen receptor has been shown to play a crucial role in inhibiting viral replication<sup>[34]</sup>. SERMs have been reported to play a broader role in inhibiting viral replication through the non-classical pathways associated with estrogen receptor<sup>[34]</sup>. SERMs interfere at the post viral entry step and affect the triggering of fusion, as the SERMs' antiviral activity still can be observed in the absence of detectable estrogen receptor expression<sup>[17]</sup>. Toremifene ( $Z = -3.23$ , **Figure 5A**), the first generation of nonsteroidal SERM, exhibits potential effects in blocking various viral infections, including MERS-CoV, SARS-CoV, and Ebola virus in established cell lines<sup>[16, 35]</sup>. Interestingly, different from the classical ESR1-related antiviral pathway, toremifene prevents fusion between the viral and endosomal membrane by interacting with and destabilizing the virus membrane glycoprotein, and eventually inhibiting viral replication<sup>[36]</sup>. As shown in **Figure 5B**, toremifene potentially affects several key host proteins associated with HCoV, such as RPL19, HNRNPA1, NPM1, EIF3I, EIF3F, and EIF3E<sup>[37, 38]</sup>. Equilin ( $Z = -2.52$  and GSEA score = 3), an estrogenic steroid produced by horses, also has been proven to have moderate activity in inhibiting the entry of Zaire Ebola virus-glycoprotein and human immunodeficiency virus (ZEBOV-GP/HIV)<sup>[17]</sup>. Altogether, network-predicted SERMs (such as toremifene and equilin) offer potential repurposable candidates for HCoVs.

**Angiotensin receptor blockers (ARBs).** ARBs have been reported to associate with viral infection, including HCoVs<sup>[39-41]</sup>. Irbesartan ( $Z = -5.98$ ), a typical ARB, was

approved by the FDA for treatment of hypertension and diabetic nephropathy. Here, network proximity analysis shows a significant association between Irbesartan's targets and HCoV-associated host proteins in the human interactome. As shown in **Figure 5C**, irbesartan targets SLC10A1, encoding the sodium/bile acid cotransporter (NTCP) protein that has been identified as a functional preS1-specific receptor for the hepatitis B virus (HBV) and the hepatitis delta virus (HDV). Irbesartan can inhibit NTCP, thus inhibiting viral entry<sup>[42, 43]</sup>. SLC10A1 interacts with C11orf74, a potential transcriptional repressor that interacts with nsp-10 of SARS-CoV<sup>[44]</sup>. There are several other ARBs (such as elexipant, frovatriptan, and zolmitriptan) in which their targets are potentially associated with HCoV-associated host proteins in the human interactome.

**Immunosuppressant or antineoplastic agents.** Previous studies have confirmed the mammalian target of rapamycin complex 1 (mTORC1) as the key factor in regulating various viruses' replications, including Andes orthohantavirus and coronavirus<sup>[45, 46]</sup>. Sirolimus ( $Z = -2.35$  and GSEA score = 3), an inhibitor of mammalian target of rapamycin (mTOR), was reported to effectively block viral protein expression and virion release effectively<sup>[47]</sup>. Indeed, the latest study revealed the clinical application: sirolimus reduced MERS-CoV infection by over 60%<sup>[48]</sup>. Moreover, sirolimus usage in managing patients with severe H1N1 pneumonia and acute respiratory failure can improve those patients' prognosis significantly<sup>[47]</sup>. Mercaptopurine ( $Z = -2.44$  and GSEA score = 1), an antineoplastic agent with immunosuppressant property, has been used to treat cancer since the 1950s and expanded its application to several autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease<sup>[49]</sup>. Mercaptopurine has been reported<sup>[49]</sup> as a selective inhibitor of both

SARS-CoV and MERS-CoV by targeting papain-like protease which plays key roles in viral maturation and antagonism to interferon stimulation<sup>[50, 51]</sup>. Mechanistically, mercaptopurine potentially target several host proteins in HCoV, such as JUN, PABPC1, NPM1, and NCL<sup>[37, 52]</sup> (**Figure 5D**).

**Anti-inflammatory agents.** Inflammatory pathways play essential roles in viral infections<sup>[53, 54]</sup>. As a biogenic amine, melatonin (N-acetyl-5-methoxytryptamine) (Z = -1.72 and GSEA score = 2) plays a key role in various biological processes, and offers a potential strategy in the management of viral infections<sup>[55, 56]</sup>. Viral infections are often associated with immune-inflammatory injury, in which the level of oxidative stress increases significantly and leaves negative effects on multiple organ functions<sup>[57]</sup>. The antioxidant effect of melatonin makes it a putative candidate drug to relieve patients' clinical symptoms in antiviral treatment, even though melatonin cannot eradicate or even curb the viral replication or transcription<sup>[58, 59]</sup>. In addition, the application of melatonin may prolong patients' survival time, which may provide a chance for patients' immune systems to recover and eventually eradicate the virus. As shown in **Figure 5E**, melatonin indirectly targets several HCoV cellular targets, including ACE2, BCL2L1, JUN, and IKBKB. Eplerenone (Z = -1.59), an aldosterone receptor antagonist, is reported to have a similar anti-inflammatory effect as melatonin. By inhibiting mast-cell-derived proteinases and suppressing fibrosis, eplerenone can improve survival of mice infected with encephalomyocarditis virus<sup>[60]</sup>.

In summary, our network proximity analyses offer multiple putative repurposable drugs that target diverse cellular pathways for potential prevention and treatment of

HCoVs. However, further preclinical experiments and clinical trials are required to verify the clinical benefits of these network-predicted candidates before clinical use.

### **Network-based Identification of Potential Drug Combinations for HCoV**

Drug combinations, offering increased therapeutic efficacy and reduced toxicity, play an important role in treating various viral infections<sup>[61]</sup>. However, our ability to identify and validate effective combinations is limited by a combinatorial explosion, driven by both the large number of drug pairs and dosage combinations. In our recent study, we proposed a novel network-based methodology to identify clinically efficacious drug combinations<sup>[25]</sup>. Relying on approved drug combinations for hypertension and cancer, we found that a drug combination was therapeutically effective only if it was captured by the ‘*Complementary Exposure*’ pattern: the targets of the drugs both hit the disease module, but target separate neighborhoods (**Figure 6A**). Here we sought to identify drug combinations that may provide a synergistic effect in treating HCoVs with well-defined mechanism-of-action by network analysis. For the 16 potential repurposable drugs (**Figure 5A**), we showcased three network-predicted candidate drug combinations in the potential treatment of HCoVs.

**Sirolimus plus Dactinomycin.** Sirolimus, an inhibitor of mTOR with both antifungal and antineoplastic properties, has demonstrated to improve outcomes in patients with severe H1N1 pneumonia and acute respiratory failure<sup>[47]</sup>. The mTOR signaling plays an essential role for MERS-CoV infection<sup>[62]</sup>. Dactinomycin, also known as actinomycin D, is an approved RNA synthesis inhibitor for treatment of various cancer

types. An early study showed that dactinomycin (1 microgram/ml) inhibited the growth of feline enteric CoV<sup>[63]</sup>. As shown in **Figure 6B**, our network analysis shows that sirolimus and dactinomycin synergistically target HCoV-associated host protein subnetwork by 'Complementary Exposure' pattern, offering potential combination regimens for treatment of HCoV. Specifically, sirolimus and dactinomycin may inhibit both mTOR signaling and RNA synthesis pathway (including DNA topoisomerase 2-alpha (TOP2A) and DNA topoisomerase 2-beta (TOP2B)) in HCoV infected cells (**Figure 6B**).

**Toremifene plus Emodin.** Toremifene is the approved first generation nonsteroidal SERMs for the treatment of metastatic breast cancer<sup>[64]</sup>. SERMs (including toremifene) inhibited Ebola virus infection<sup>[17]</sup> by interacting with and destabilizing the Ebola virus glycoprotein<sup>[36]</sup>. *In vitro* assays have demonstrated that toremifene inhibited growth of MERS-CoV<sup>[16, 65]</sup> and SARA-CoV<sup>[35]</sup> (**Table 1**). Emodin, an anthraquinone derivative extracted from the roots of rheum tanguticum, have been reported to have various anti-virus effects. Specifically, emdoin inhibited SARS-CoV associated 3a protein<sup>[66]</sup>, and blocked an interaction between the SARS-CoV spike protein and ACE2<sup>[67]</sup>. Altogether, network analyses and published experimental data suggested that combining toremifene and emdoin offered a potential therapeutic approach for HCoVs (**Figure 6C**).

**Mercaptopurine plus Melatonin.** As shown in **Figure 5A**, targets of both mercaptopurine and melatonin showed strong network proximity with HCoV-associated host proteins in the human interactome network. Recent *in vitro* and *in vivo* studies identified mercaptopurine as a selective inhibitor of both SARS-CoV and MERS-CoV by targeting papain-like protease <sup>[50, 51]</sup>. Melatonin was reported in potential treatment of

viral infection via its anti-inflammatory and antioxidant effects<sup>[55-59]</sup>. Melatonin indirectly regulates ACE2 expression, a key entry receptor involved in viral infection of HCoVs, including 2019-nCoV<sup>[31]</sup>. JUN, also known as c-Jun, is a key host protein involving in HCoV infectious bronchitis virus<sup>[68]</sup>. As shown in **Figure 6D**, mercaptopurine and melatonin may synergistically block c-Jun signaling by targeting multiple cellular targets. In summary, combination of mercaptopurine and melatonin may offer a potential combination therapy for 2019-nCoV by synergistically targeting papain-like protease, ACE2, c-Jun signaling, and anti-inflammatory pathways (**Figure 6D**). However, further experimental and clinical validations are highly warranted.

## Discussion

In this study, we presented a network-based methodology for systematic identification of putative repurposable drugs and drug combinations for potential treatment of HCoV. Integration of drug-target networks, HCoV-host interactions, HCoV-induced transcriptome in human cell lines, and human protein-protein interactome network are essential for such identification. Based on comprehensive evaluation, we prioritized 16 putative repurposable drugs (**Figure 5**) and 3 putative drug combinations (**Figure 6**) for the potential treatment of HCoVs, including 2019-nCoV. However, all network-predicted repurposable drugs and drug combinations must be validated in preclinical models and randomized clinical trials before being used in patients.

We acknowledge several limitations in our current study. In this study, we used a low binding affinity value of 10  $\mu$ M as a threshold to define a physical drug-target



interaction. However, a stronger binding affinity threshold (e.g., 1 $\mu$ M) may be a more suitable cut-off in drug discovery, although it will generate a smaller drug-target network. Although sizeable efforts were made for assembling large-scale, experimentally reported drug-target networks from publicly available databases, the network data may be incomplete and some drug-protein interactions may be functional associations, instead of physical bindings. We may use computational approaches to systematically predict the drug-target interactions further<sup>[24, 69]</sup>. In addition, the collected virus-host interactions are far from complete and the quality can be influenced by multiple factors, including different experimental assays and human cell line models. We may computationally predict a new virus-host interactome for HCoVs using sequence-based and structure-based approaches<sup>[70]</sup>. The current systems pharmacology model cannot separate therapeutic antiviral effects from those predictions due to lack of detailed pharmacological effects of drug targets and unknown functional consequences of virus-host interactions. Drug targets representing nodes within cellular networks are often intrinsically coupled with both therapeutic and adverse profiles<sup>[71]</sup>, as drugs can inhibit or activate protein functions (including antagonists versus agonists). Comprehensive identification of the virus-host interactome for 2019-nCoV, with specific biological effects using functional genomics assays<sup>[72, 73]</sup>, will significantly improve the accuracy of current network-based methodologies.

Owing to lack of the complete drug target information (such as the molecular ‘promiscuity’ of drugs), the dose-response and dose-toxicity effects for both repurposable drugs and drug combinations cannot be identified in current network models. For example, Mesalazine, an approved drug for inflammatory bowel disease, is

a top network-predicted candidate drug (**Figure 5A**) associated with HCoV. Yet, several clinical studies showed the potential pulmonary toxicities (including pneumonia) associated with mesalazine usage [74, 75]. Preclinical studies are warranted to evaluate *in vivo* efficiency and side effects before clinical trials. Furthermore, we only limited to predict pairwise drug combinations based on our previous network-based framework<sup>[25]</sup>. However, we expect that our methodology reminds to be a useful network-based tools for prediction of combining multiple drugs toward exploring network relationships of multiple drugs' targets with the HCoV-host subnetwork in the human interactome. Finally, we aimed to systematically identify repurposable drugs by specifically targeting nCoV host proteins only. Thus, our current network models cannot predict repurposable drugs from the existing anti-virus drugs that target virus proteins only. Thus, combination of the existing anti-virus drugs (such as remdesivir<sup>[76]</sup>) with the network-predicted repurposable drugs (**Figure 5**) or drug combinations (**Figure 6**) may improve coverage of current network-based methodologies by utilizing multi-layer network framework.

In conclusion, this study offers a powerful, integrated network-based systems pharmacology methodology for rapid identification of repurposable drugs and drug combinations for the potential treatment of HCoV. Our approach can minimize the translational gap between preclinical testing results and clinical outcomes, which is a significant problem in the rapid development of efficient treatment strategies for the emerging 2019-nCoV outbreak. From a translational perspective, if broadly applied, the network tools developed here could help develop effective treatment strategies for other types of virus and human diseases as well.

## Methods and Materials

### Genome Information and Phylogenetic analysis

In total, we collected DNA sequences and protein sequences for 15 HCoV, including three most recent 2019-nCoV genomes, from the NCBI GenBank database (January 28, 2020, Supplementary **Table S1**). Whole genome alignment and protein sequence identity calculation were performed by Multiple Sequence Alignment in EMBL-EBI database with default parameters. The neighbor joining (NJ) tree was computed from the pairwise phylogenetic distance matrix using MEGA X<sup>[77]</sup> with 1000 bootstrap replicates. The protein alignment and phylogenetic tree of HCoVs were constructed by MEGA X.

### Building the Virus-Host Interactome

We collected HCoV-host protein interactions from various literatures based on our sizeable efforts. The HCoV-associated host proteins of several HCoVs, including SARS-CoV, MERS-CoV, IBV, MHV, HCoV-229E, and HCoV-NL63 were pooled. These proteins were either the direct targets of HCoV proteins or were involved in critical pathways of HCoV infection identified by multiple experimental sources, including high throughput yeast-two-hybrid (Y2H) systems, viral protein pull-down assay, *in vitro* co-immunoprecipitation and RNA knock down experiment. In total, the virus-host interaction network included 6 HCoVs with 119 host proteins (Supplementary **Table S3**).

## **Functional Enrichment Analysis**

Next, we performed Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analyses to evaluate the biological relevance and functional pathways of the HCoV-associated proteins. All functional analyses were performed using Enrichr<sup>[78]</sup>.

## **Building the Drug-Target Network**

Here, we collected drug-target interaction information from the DrugBank database (v4.3)<sup>[79]</sup>, Therapeutic Target Database (TTD)<sup>[80]</sup>, PharmGKB database, ChEMBL (v20)<sup>[81]</sup>, BindingDB<sup>[82]</sup>, and IUPHAR/BPS Guide to PHARMACOLOGY<sup>[83]</sup>. The chemical structure of each drug with SMILES format was extracted from DrugBank<sup>[79]</sup>. Here, only drug-target interactions meeting the following three criteria were used: (i) binding affinities, including  $K_i$ ,  $K_d$ ,  $IC_{50}$  or  $EC_{50}$  each  $\leq 10 \mu\text{M}$ ; (ii) the target was marked as 'reviewed' in the UniProt database<sup>[84]</sup>; and (iii) the human target was represented by a unique UniProt accession number. The details for building the experimentally validated drug-target network are provided in our recent study<sup>[12]</sup>.

## **Building the Human Protein-Protein Interactome**

To build a comprehensive list of human PPIs, we assembled data from a total of 18 bioinformatics and systems biology databases with five types of experimental

evidences: (i) Binary PPIs tested by high-throughput yeast-two-hybrid (Y2H) systems; (ii) Binary, physical PPIs from protein three-dimensional (3D) structures; (iii) Kinase-substrate interactions by literature-derived low-throughput or high-throughput experiments; (iv) Signaling network by literature-derived low-throughput experiments; and (v) Literature-curated PPIs identified by affinity purification followed by mass spectrometry (AP-MS), Y2H, or by literature-derived low-throughput experiments. All inferred data, including evolutionary analysis, gene expression data, and metabolic associations, were excluded. The genes were mapped to their Entrez ID based on the NCBI database<sup>[85]</sup> as well as their official gene symbols based on GeneCards (<https://www.genecards.org/>). In total, the resulting human protein-protein interactome used in this study includes 351,444 unique PPIs (edges or links) connecting 17,706 proteins (nodes), representing a 50% increase in the number of the PPIs we have used previously. Detailed descriptions for building the human protein-protein interactome are provided in our previous studies<sup>[12, 86, 87]</sup>.

## Network Proximity Measure

We posit that the human PPIs provide an unbiased, rational roadmap for repurposing drugs for potential treatment of HCoV in which they were not originally approved. Given  $C$ , the set of host genes associated with a specific HCoV, and  $T$ , the set of drug targets, we computed the network proximity of  $C$  with the target set  $T$  of each drug using the “closest” method:

$$\langle d_{CT} \rangle = \frac{1}{\|C\| + \|T\|} \left( \sum_{c \in C} \min_{t \in T} d(c, t) + \sum_{t \in T} \min_{c \in C} d(c, t) \right) \quad (1)$$

where  $d(c, t)$  is the shortest distance between gene  $c$  and  $t$  in the human protein interactome. The network proximity was converted to Z-score based on permutation tests:

$$Z_{d_{CT}} = \frac{d_{CT} - \bar{d}_r}{\sigma_r} \quad (2)$$

where  $\bar{d}_r$  and  $\sigma_r$  were the mean and standard deviation of the permutation test repeated 1,000 times, each time with two randomly selected gene lists with similar degree distributions to those of  $C$  and  $T$ . The corresponding  $P$  value was calculated based on the permutation test results. Z-score  $< -1.5$  and  $P < 0.05$  were considered significantly proximal drug-HCoV associations. All networks were visualized using Gephi 0.9.2 (<https://gephi.org/>).

## Network-based Rational Design of Drug Combination Prediction

For this network-based approach for drug combinations to be effective, we need to establish if the topological relationship between two drug-target modules reflects biological and pharmacological relationships, while also quantifying their network-based relationship between drug-targets and HCoV-associated host proteins (drug-drug-HCoV combinations). To identify potential drug combinations, we combined the top lists of drugs. Then, “separation” measure  $S_{AB}$  was calculated for each pair of drugs  $A$  and  $B$  using the following method:

$$S_{AB} = \langle d_{AB} \rangle - \frac{\langle d_{AA} \rangle + \langle d_{BB} \rangle}{2} \quad (3)$$

where  $\langle d. \rangle$  was calculated based on the “closest” method. Our key methodology is that a drug combination is therapeutically effective only if it follows a specific relationship to the disease module, as captured by *Complementary Exposure* patterns in targets’ modules of both drugs without overlapping toxic mechanisms.<sup>[25]</sup>

## Gene Set Enrichment Analysis

We performed the gene set enrichment analysis as an additional prioritization method. We first collected three differential gene expression data sets of hosts infected by HCoVs from the NCBI Gene Expression Omnibus (GEO). Among them, two transcriptome data sets were SARS-CoV infected samples from patient’s peripheral blood<sup>[88]</sup> (GSE1739) and Calu-3 cells<sup>[89]</sup> (GSE33267) respectively. One transcriptome data set was MERS-CoV infected Calu-3 cells<sup>[90]</sup> (GSE122876). Adjusted  $P$  value less than 0.01 was defined as differentially expressed genes. These data sets were used as HCoV host signatures to evaluate the treatment effects of drugs. Differential gene expression in cells treated with various drugs were retrieved from the Connectivity Map (CMAP) database<sup>[33]</sup>, and were used as gene profiles for the drugs. For each drug that was in both the CMAP data set and our drug-target network, we calculated an enrichment score ( $ES$ ) for each HCoV signature data set based on previously described methods<sup>[91]</sup> as follows:

$$ES = \begin{cases} ES_{up} - ES_{down}, & \text{sgn}(ES_{up}) \neq \text{sgn}(ES_{down}) \\ 0, & \text{else} \end{cases} \quad (4)$$

$ES_{up}$  and  $ES_{down}$  were calculated separately for the up- and down-regulated genes from the HCoV signature data set using the same method. We first computed  $a_{up/down}$  and  $b_{up/down}$  as:

$$a = \max_{1 \leq j \leq s} \left( \frac{j}{s} - \frac{V(j)}{r} \right) \quad (5)$$

$$b = \max_{1 \leq j \leq s} \left( \frac{V(j)}{r} - \frac{j-1}{s} \right) \quad (6)$$

where  $j = 1, 2, \dots, s$  were the genes of HCoV signature data set sorted in ascending order by their rank in the gene profiles of the drug being evaluated. The rank of gene  $j$  is denoted by  $V(j)$ , where  $1 \leq V(j) \leq r$ , with  $r$  being the number of genes (12,849) from the drug profile. Then,  $ES_{up/down}$  was set to  $a_{up/down}$  if  $a_{up/down} > b_{up/down}$ , and was set to  $-b_{up/down}$  if  $b_{up/down} > a_{up/down}$ . Permutation tests repeated 100 times using randomly generated gene lists with the same number of up- and down-regulated genes as the HCoV signature data set were performed to measure the significance of the  $ES$  scores. Drugs were considered to have potential treatment effect if  $ES > 0$  and  $P < 0.05$ , and the number of such HCoV signature data sets were used as the final GSEA score that ranges from 0 to 3. "NA" indicates that the drug cannot be evaluated by this method due to the lack of the drug profile.



## AUTHOR CONTRIBUTIONS

F.C. conceived the study. Y.Z. and Y.H. developed the network methodology and performed all computational experiments. J.S., Y.Z., Y.H., Y.H., and W.M. performed data analysis. F.C., Y.Z. and Y.H. and J.S. wrote and critically revised the manuscript with contributions from other co-authors.

**Competing Interests:** The content of this publication does not necessarily reflect the views of the Cleveland Clinic. The authors declare no competing interests.

**Data and Code Availability:** All codes and predicted repurposable drugs can be freely accessed at: <https://github.com/ChengF-Lab/2019-nCoV>

## References

1. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. *Nat Rev Drug Discov.* 2016; 15(5):327-47. doi: 10.1038/nrd.2015.37.
2. Paules CI, Marston HD, Fauci AS. Coronavirus Infections-More Than Just the Common Cold. *JAMA.* 2020. doi: 10.1001/jama.2020.0757.
3. de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. *Nat Rev Microbiol.* 2016; 14(8):523-34. doi: 10.1038/nrmicro.2016.81.
4. de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host Factors in Coronavirus Replication. *Curr Top Microbiol Immunol.* 2018; 419:1-42. doi: 10.1007/82\_2017\_25.
5. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Li M, Tu W, Chen C, Jin L, Yang R,

Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam TTY, Wu JTK, Gao GF, Cowling BJ, Yang B, Leung GM, Feng Z. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med*. 2020. doi: 10.1056/NEJMoa2001316.

6. Greene JA, Loscalzo J. Putting the patient back together - Social medicine, network medicine, and the limits of reductionism. *N Engl J Med*. 2017; 377(25):2493-9. doi: 10.1056/NEJMms1706744.

7. Avorn J. The \$2.6 billion pill--methodologic and policy considerations. *N Engl J Med*. 2015; 372(20):1877-9. doi: 10.1056/NEJMp1500848.

8. Cheng F. In silico oncology drug repositioning and polypharmacology. *Methods Mol Biol*. 2019; 1878:243-61. doi: 10.1007/978-1-4939-8868-6\_15.

9. Cheng F, Hong H, Yang S, Wei Y. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. *Brief Bioinform*. 2017; 18(4):682-97. doi: 10.1093/bib/bbw051.

10. Cheng F, Murray JL, Rubin DH. Drug repurposing: New treatments for Zika virus infection? *Trends Mol Med*. 2016; 22(11):919-21. doi: 10.1016/j.molmed.2016.09.006.

11. Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP. A comprehensive map of molecular drug targets. *Nat Rev Drug Discov*. 2017; 16(1):19-34. doi: 10.1038/nrd.2016.230.

12. Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabasi AL, Loscalzo J. Network-based approach to prediction and population-based validation of in silico drug repurposing. *Nat Commun*. 2018; 9(1):2691. doi: 10.1038/s41467-018-05116-5.

13. Cheng F, Murray JL, Zhao J, Sheng J, Zhao Z, Rubin DH. Systems biology-based investigation of cellular antiviral drug targets identified by gene-trap insertional mutagenesis. *PLoS Comput Biol*. 2016; 12(9):e1005074. doi: 10.1371/journal.pcbi.1005074.

14. Yang S, Fu C, Lian X, Dong X, Zhang Z. Understanding human-virus protein-protein interactions using a human protein complex-based analysis framework. *mSystems*. 2019; 4(2). doi: 10.1128/mSystems.00303-18.

15. Liu C, Ma Y, Zhao J, Nussinov R, Zhang Y, Cheng F, Zhang Z. Computational network biology: Data, models, and applications. DOI: 10.1016/j.physrep.2019.12.004. *Physics Reports*. 2020.

16. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG, Jr., Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB. Repurposing of clinically developed drugs for treatment of Middle

East respiratory syndrome coronavirus infection. *Antimicrob Agents Chemother.* 2014; 58(8):4885-93. doi: 10.1128/AAC.03036-14.

17. Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehar J, Hensley LE, White JM, Olinger GG. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. *Sci Transl Med.* 2013; 5(190):190ra79. doi: 10.1126/scitranslmed.3005471.

18. He S, Lin B, Chu V, Hu Z, Hu X, Xiao J, Wang AQ, Schweitzer CJ, Li Q, Imamura M, Hiraga N, Southall N, Ferrer M, Zheng W, Chayama K, Marugan JJ, Liang TJ. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. *Sci Transl Med.* 2015; 7(282):282ra49. doi: 10.1126/scitranslmed.3010286.

19. Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Munoz G, McGrath EL, Urrabaz-Garza R, Gao J, Wu P, Menon R, Saade G, Fernandez-Salas I, Rossi SL, Vasilakis N, Routh A, Bradrick SS, Garcia-Blanco MA. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. *Cell Host Microbe.* 2016; 20(2):259-70. doi: 10.1016/j.chom.2016.07.004.

20. Xu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, Tcw J, Kouznetsova J, Ogden SC, Hammack C, Jacob F, Nguyen HN, Itkin M, Hanna C, Shinn P, Allen C, Michael SG, Simeonov A, Huang W, Christian KM, Goate A, Brennand KJ, Huang R, Xia M, Ming GL, Zheng W, Song H, Tang H. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. *Nat Med.* 2016; 22(10):1101-7. doi: 10.1038/nm.4184.

21. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G, Zhou W, Huang J, Tang Y. Prediction of drug-target interactions and drug repositioning via network-based inference. *PLoS Comput Biol.* 2012; 8(5):e1002503. doi: 10.1371/journal.pcbi.1002503.

22. Cheng F, Lu W, Liu C, Fang J, Hou Y, Handy DE, Wang R, Zhao Y, Yang Y, Huang J, Hill DE, Vidal M, Eng C, Loscalzo J. A genome-wide positioning systems network algorithm for in silico drug repurposing. *Nat Commun.* 2019; 10(1):3476. doi: 10.1038/s41467-019-10744-6.

23. Zeng X, Zhu S, Liu X, Zhou Y, Nussinov R, Cheng F. deepDR: a network-based deep learning approach to in silico drug repositioning. *Bioinformatics.* 2019; 35(24):5191-8. doi: 10.1093/bioinformatics/btz418.

24. Zeng X, Zhu S, Lu W, Liu Z, Huang J, Zhou Y, Hou Y, Huang Y, Guo H, Fang J, Liu M, Trapp D, Li L, Nussinov R, Eng C, Loscalzo J, Cheng F. Target identification among known drugs by deep learning from heterogeneous networks. *Chemical Science.* 2019; DOI: 10.1039/C9SC04336E.

25. Cheng F, Kovacs IA, Barabasi AL. Network-based prediction of drug combinations. *Nat Commun.* 2019; 10(1):1197. doi: 10.1038/s41467-019-09186-x.
26. Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J, Barabasi AL. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. *Science.* 2015; 347(6224):1257601. doi: 10.1126/science.1257601.
27. Forni D, Cagliani R, Clerici M, Sironi M. Molecular Evolution of Human Coronavirus Genomes. *Trends Microbiol.* 2017; 25(1):35-48. doi: 10.1016/j.tim.2016.09.001.
28. Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. *Nat Commun.* 2019; 10(1):2342. doi: 10.1038/s41467-019-10280-3.
29. Li F, Li W, Farzan M, Harrison SC. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor. *Science.* 2005; 309(5742):1864-8. doi: 10.1126/science.1116480.
30. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet.* 2020. doi: 10.1016/s0140-6736(20)30251-8.
31. Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, Si H, Zhu Y, Li B, Huang C, Chen H, Chen J, Luo Y, Guo H, Jiang R, Liu M, Chen Y, Shen X, Wang X, Zheng X, Zhao K, Chen Q, Deng F, Liu L, Yan B, Zhan F, Wang Y, Xiao G, Shi Z. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. 2020, bioRxiv available: <https://www.biorxiv.org/content/10.1101/2020.01.22.914952v2.full.pdf>.
32. Chang CK, Chen CM, Chiang MH, Hsu YL, Huang TH. Transient oligomerization of the SARS-CoV N protein--implication for virus ribonucleoprotein packaging. *PLoS One.* 2013; 8(5):e65045. doi: 10.1371/journal.pone.0065045.
33. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science.* 2006; 313(5795):1929-35. doi: 10.1126/science.1132939.
34. Lasso G, Mayer SV, Winkelmann ER, Chu T, Elliot O, Patino-Galindo JA, Park K, Rabadan R, Honig B, Shapira SD. A Structure-Informed Atlas of Human-Virus Interactions. *Cell.* 2019; 178(6):1526-41.e16. doi: 10.1016/j.cell.2019.08.005.

35. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. *Antimicrob Agents Chemother*. 2014; 58(8):4875-84. doi: 10.1128/AAC.03011-14.
36. Zhao Y, Ren J, Harlos K, Jones DM, Zeltina A, Bowden TA, Padilla-Parra S, Fry EE, Stuart DI. Toremfene interacts with and destabilizes the Ebola virus glycoprotein. *Nature*. 2016; 535(7610):169-72. doi: 10.1038/nature18615.
37. Emmott E, Munday D, Bickerton E, Britton P, Rodgers MA, Whitehouse A, Zhou EM, Hiscox JA. The cellular interactome of the coronavirus infectious bronchitis virus nucleocapsid protein and functional implications for virus biology. *J Virol*. 2013; 87(17):9486-500. doi: 10.1128/JVI.00321-13.
38. V'Kovski P, Gerber M, Kelly J, Pfaender S, Ebert N, Braga Lagache S, Simillion C, Portmann J, Stalder H, Gaschen V, Bruggmann R, Stoffel MH, Heller M, Dijkman R, Thiel V. Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling. *Elife*. 2019; 8. doi: 10.7554/eLife.42037.
39. Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. *Curr Top Med Chem*. 2004; 4(13):1433-54. doi: 10.2174/1568026043387818.
40. Seko Y. Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3. *Clin Sci (Lond)*. 2006; 110(3):379-86. doi: 10.1042/CS20050299.
41. Erlandson KM, Kitch D, Wester CW, Kalayjian RC, Overton ET, Castillo-Mancilla J, Koletar SL, Benson CA, Campbell TB, Robertson K, Lok JJ. The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults With Human Immunodeficiency Virus Infection. *Clin Infect Dis*. 2017; 65(12):2042-9. doi: 10.1093/cid/cix645.
42. Wang XJ, Hu W, Zhang TY, Mao YY, Liu NN, Wang SQ. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity. *Antiviral Res*. 2015; 120:140-6. doi: 10.1016/j.antiviral.2015.06.007.
43. Ko C, Park WJ, Park S, Kim S, Windisch MP, Ryu WS. The FDA-approved drug irbesartan inhibits HBV-infection in HepG2 cells stably expressing sodium taurocholate co-transporting polypeptide. *Antivir Ther*. 2015; 20(8):835-42. doi: 10.3851/IMP2965.

44. Hong M, Li W, Wang L, Jiang L, Liu L, Zhao H, Li Q. Identification of a novel transcriptional repressor (HEPIS) that interacts with nsp-10 of SARS coronavirus. *Viral Immunol.* 2008; 21(2):153-62. doi: 10.1089/vim.2007.0108.
45. McNulty S, Flint M, Nichol ST, Spiropoulou CF. Host mTORC1 signaling regulates andes virus replication. *J Virol.* 2013; 87(2):912-22. doi: 10.1128/jvi.02415-12.
46. Stohr S, Costa R, Sandmann L, Westhaus S, Pfaender S, Anggakusuma, Dazert E, Meuleman P, Vondran FW, Manns MP, Steinmann E, von Hahn T, Ciesek S. Host cell mTORC1 is required for HCV RNA replication. *Gut.* 2016; 65(12):2017-28. doi: 10.1136/gutjnl-2014-308971.
47. Wang CH, Chung FT, Lin SM, Huang SY, Chou CL, Lee KY, Lin TY, Kuo HP. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. *Crit Care Med.* 2014; 42(2):313-21. doi: 10.1097/CCM.0b013e3182a2727d.
48. Dyall J, Gross R, Kindrachuk J, Johnson RF, Olinger GG, Jr., Hensley LE, Frieman MB, Jahrling PB. Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. *Drugs.* 2017; 77(18):1935-66. doi: 10.1007/s40265-017-0830-1.
49. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. *Nat Rev Cancer.* 2008; 8(1):24-36. doi: 10.1038/nrc2292.
50. Chen X, Chou CY, Chang GG. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. *Antivir Chem Chemother.* 2009; 19(4):151-6. doi: 10.1177/095632020901900402.
51. Cheng KW, Cheng SC, Chen WY, Lin MH, Chuang SJ, Cheng IH, Sun CY, Chou CY. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. *Antiviral Res.* 2015; 115:9-16. doi: 10.1016/j.antiviral.2014.12.011.
52. Chen H, Wurm T, Britton P, Brooks G, Hiscox JA. Interaction of the coronavirus nucleoprotein with nucleolar antigens and the host cell. *J Virol.* 2002; 76(10):5233-50. doi: 10.1128/jvi.76.10.5233-5250.2002.
53. Rainsford KD. Influenza ("Bird Flu"), inflammation and anti-inflammatory/analgesic drugs. *Inflammopharmacology.* 2006; 14(1-2):2-9. doi: 10.1007/s10787-006-0002-5.
54. Garcia CC, Guabiraba R, Soriani FM, Teixeira MM. The development of anti-inflammatory drugs for infectious diseases. *Discov Med.* 2010; 10(55):479-88.

55. Silvestri M, Rossi GA. Melatonin: its possible role in the management of viral infections-- a brief review. *Ital J Pediatr.* 2013; 39:61. doi: 10.1186/1824-7288-39-61.
56. Srinivasan V, Mohamed M, Kato H. Melatonin in bacterial and viral infections with focus on sepsis: a review. *Recent Pat Endocr Metab Immune Drug Discov.* 2012; 6(1):30-9. doi: 10.2174/187221412799015317.
57. Tan DX, Korkmaz A, Reiter RJ, Manchester LC. Ebola virus disease: potential use of melatonin as a treatment. *J Pineal Res.* 2014; 57(4):381-4. doi: 10.1111/jpi.12186.
58. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? *J Pineal Res.* 2007; 42(1):28-42. doi: 10.1111/j.1600-079X.2006.00407.x.
59. Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. *J Pineal Res.* 2013; 54(3):245-57. doi: 10.1111/jpi.12010.
60. Xiao J, Shimada M, Liu W, Hu D, Matsumori A. Anti-inflammatory effects of eplerenone on viral myocarditis. *Eur J Heart Fail.* 2009; 11(4):349-53. doi: 10.1093/eurjhf/hfp023.
61. Tan X, Hu L, Luquette LJ, 3rd, Gao G, Liu Y, Qu H, Xi R, Lu ZJ, Park PJ, Elledge SJ. Systematic identification of synergistic drug pairs targeting HIV. *Nat Biotechnol.* 2012; 30(11):1125-30. doi: 10.1038/nbt.2391.
62. Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. *Antimicrob Agents Chemother.* 2015; 59(2):1088-99. doi: 10.1128/AAC.03659-14.
63. Lewis EL, Harbour DA, Beringer JE, Grinsted J. Differential in vitro inhibition of feline enteric coronavirus and feline infectious peritonitis virus by actinomycin D. *J Gen Virol.* 1992; 73 ( Pt 12):3285-8. doi: 10.1099/0022-1317-73-12-3285.
64. Zhou WB, Ding Q, Chen L, Liu XA, Wang S. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. *Breast Cancer Res Treat.* 2011; 128(3):625-31. doi: 10.1007/s10549-011-1556-5.
65. Cong Y, Hart BJ, Gross R, Zhou H, Frieman M, Bollinger L, Wada J, Hensley LE, Jahrling PB, Dyall J, Holbrook MR. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. *PLoS One.* 2018; 13(3):e0194868. doi: 10.1371/journal.pone.0194868.













66. Schwarz S, Wang K, Yu W, Sun B, Schwarz W. Emodin inhibits current through SARS-associated coronavirus 3a protein. *Antiviral Res.* 2011; 90(1):64-9. doi: 10.1016/j.antiviral.2011.02.008.
67. Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. *Antiviral Res.* 2007; 74(2):92-101. doi: 10.1016/j.antiviral.2006.04.014.
68. Fung TS, Liu DX. Activation of the c-Jun NH2-terminal kinase pathway by coronavirus infectious bronchitis virus promotes apoptosis independently of c-Jun. *Cell Death Dis.* 2017; 8(12):3215. doi: 10.1038/s41419-017-0053-0.
69. Zeng X, Zhu S, Hou Y, Zhang P, Li L, Li J, Huang LF, Lewis SJ, Nussinov R, Cheng F. Network-based prediction of drug-target interactions using an arbitrary-order proximity embedded deep forest. *Bioinformatics.* 2020. doi: 10.1093/bioinformatics/btaa010.
70. Halder AK, Dutta P, Kundu M, Basu S, Nasipuri M. Review of computational methods for virus-host protein interaction prediction: a case study on novel Ebola-human interactions. *Brief Funct Genomics.* 2018; 17(6):381-91. doi: 10.1093/bfgp/elx026.
71. Bedi O, Dhawan V, Sharma PL, Kumar P. Pleiotropic effects of statins: new therapeutic targets in drug design. *Naunyn Schmiedebergs Arch Pharmacol.* 2016; 389(7):695-712. doi: 10.1007/s00210-016-1252-4.
72. Li Q, Zhang YY, Chiu S, Hu Z, Lan KH, Cha H, Sodroski C, Zhang F, Hsu CS, Thomas E, Liang TJ. Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle. *PLoS Pathog.* 2014; 10(5):e1004163. doi: 10.1371/journal.ppat.1004163.
73. Gebre M, Nomburg JL, Gewurz BE. CRISPR-Cas9 Genetic Analysis of Virus-Host Interactions. *Viruses.* 2018; 10(2). doi: 10.3390/v10020055.
74. Kim JH, Lee JH, Koh ES, Park SW, Jang AS, Kim D, Park CS. Acute eosinophilic pneumonia related to a mesalazine suppository. *Asia Pac Allergy.* 2013; 3(2):136-9. doi: 10.5415/apallergy.2013.3.2.136.
75. Gupta A, Gulati S. Mesalamine induced eosinophilic pneumonia. *Respir Med Case Rep.* 2017; 21:116-7. doi: 10.1016/j.rmcr.2017.04.010.
76. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun.* 2020; 11(1):222. doi: 10.1038/s41467-019-13940-6.








77. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. *Mol Biol Evol.* 2018; 35(6):1547-9. doi: 10.1093/molbev/msy096.
78. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma'ayan A. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Research.* 2016; 44(W1):W90-W7. doi: 10.1093/nar/gkw377.
79. Law V, Knox C, Djombou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS. DrugBank 4.0: shedding new light on drug metabolism. *Nucleic Acids Res.* 2014; 42(Database issue):D1091-7. doi: 10.1093/nar/gkt1068.
80. Yang H, Qin C, Li YH, Tao L, Zhou J, Yu CY, Xu F, Chen Z, Zhu F, Chen YZ. Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information. *Nucleic Acids Res.* 2016; 44(D1):D1069-74. doi: 10.1093/nar/gkv1230.
81. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Research.* 2012; 40(D1):D1100-D7. doi: 10.1093/nar/gkr777.
82. Liu TQ, Lin YM, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. *Nucleic Acids Research.* 2007; 35:D198-D201. doi: 10.1093/nar/gkl999.
83. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SPH, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu WY, Harmar AJ, Nc I. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. *Nucleic Acids Research.* 2014; 42(D1):D1098-D106. doi: 10.1093/nar/gkt1143.
84. Apweiler R, Bairoch A, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang HZ, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, Redaschi N, Yeh LSL. UniProt: the Universal Protein knowledgebase. *Nucleic Acids Research.* 2004; 32:D115-D9. doi: 10.1093/nar/gkh131.
85. Coordinators NR. Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.* 2016; 44(D1):D7-19. doi: 10.1093/nar/gkv1290.

86. Cheng F, Jia P, Wang Q, Lin CC, Li WH, Zhao Z. Studying tumorigenesis through network evolution and somatic mutational perturbations in the cancer interactome. *Mol Biol Evol.* 2014; 31(8):2156-69. doi: 10.1093/molbev/msu167.
87. Cheng F, Liu C, Lin CC, Zhao J, Jia P, Li WH, Zhao Z. A Gene Gravity Model for the Evolution of Cancer Genomes: A Study of 3,000 Cancer Genomes across 9 Cancer Types. *PLoS Comput Biol.* 2015; 11(9):e1004497. doi: 10.1371/journal.pcbi.1004497.
88. Reghunathan R, Jayapal M, Hsu L-Y, Chng H-H, Tai D, Leung BP, Melendez AJ. Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. *BMC Immunology.* 2005; 6(1):2. doi: 10.1186/1471-2172-6-2.
89. Josset L, Menachery VD, Gralinski LE, Agnihothram S, Sova P, Carter VS, Yount BL, Graham RL, Baric RS, Katze MG. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. *mBio.* 2013; 4(3):e00165-13. doi: 10.1128/mBio.00165-13.
90. Yuan S, Chu H, Chan JF-W, Ye Z-W, Wen L, Yan B, Lai P-M, Tee K-M, Huang J, Chen D, Li C, Zhao X, Yang D, Chiu MC, Yip C, Poon VK-M, Chan CC-S, Sze K-H, Zhou J, Chan IH-Y, Kok K-H, To KK-W, Kao RY-T, Lau JY-N, Jin D-Y, Perlman S, Yuen K-Y. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. *Nature Communications.* 2019; 10(1):120. doi: 10.1038/s41467-018-08015-x.
91. Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ. Discovery and preclinical validation of drug indications using compendia of public gene expression data. *Sci Transl Med.* 2011; 3(96):96ra77. doi: 10.1126/scitranslmed.3001318.

**Table 1. Top drug candidates from network-based repurposing approach with literature antiviral evidences.**

Z-score	DrugBank ID	Drug Name	Structure	Category	Therapeutic effect on virus	PubMed ID
-5.98	DB01029	Irbesartan		antihypertensive	HBV, HDV	25929767, 26086883, 24717262
-3.23	DB00539	Toremifene		antineoplastic	EBOV, MERS-CoV, SARS-CoV	27362232, 29566060, 24841273, 24841269
-2.64	DB01744	Camphor		antipruritic, anti-infective	H1N1	27823881, 30165308
-2.52	DB02187	Equilin		estrogen	ZEBOV-GP/HIV	27169275
-2.44	DB00244	Mesalazine		anti-inflammatory	EBV	25914477
-2.44	DB01033	Mercaptopurine		antimetabolite, antineoplastic	SARS-CoV, MERS-CoV	18313035, 19374142, 25542975
-2.42	DB00715	Paroxetine		selective serotonin reuptake inhibitor	EBOV	29272110
-2.35	DB00877	Sirolimus		immunosuppressants	ANDV, HCV	23135723, 26276683, 29143192, 24105455
-1.94	DB01136	Carvedilol		beta-blocker	EMCV	12535832
-1.92	DB01394	Colchicine		anti-inflammatory	EBV	28795759
-1.88	DB00970	Dactinomycin		antineoplastic	FECV	1335030
-1.72	DB01065	Melatonin		hormone	EBOV, RSV	25262626, 20070490

-1.62	DB01103	Quinacrine		antimalarial, antibiotic	EV71, EBOV	23301007, 31307979, 27890675
-1.59	DB00700	Eplerenone		diuretic	viral myocarditis	19213804
-1.54	DB07715	Emodin		anthraquinones	HSV-1, HSV-2, HBV, SARS-CoV, CVB <sub>4</sub>	21050882, 16940925, 21356245, 16730806, 24071990
-1.53	DB06412	Oxymetholone		anabolic steroid	HIV wasting	12815555
-1.49	DB02709	Resveratrol		polyphenolic phytoalexin	MERS-CoV	29495250

HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis delta virus; EBOV, Ebola viruses; ZEBOV-GP, Zaire Ebola virus-glycoprotein; HIV, human immunodeficiency virus; EBV, Epstein-Barr virus; ANDV, Andes orthohantavirus; EMCV, encephalomyocarditis virus; FECV, feline enteric coronavirus; RSV, respiratory syncytial virus; EV71, enterovirus 71; HSV-1 and -2, Herpes simplex viruses; CVB<sub>4</sub>, Coxsackievirus B<sub>4</sub>.

## Figure Legends

**Figure 1. Overall workflow of this study.** Our network-based methodology combines a systems pharmacology-based network medicine platform that quantifies the interplay between the virus-host interactome and drug targets in the human PPI network. **(A)** Human coronavirus (HCoV) associated host proteins were collected from literatures and pooled to generate a pan-HCoV protein subnetwork. **(B)** Network proximity between drug targets and HCoV-associated proteins was calculated to screen for candidate repurposable drugs for HCoVs under the human protein interactome model. **(C & D)** Gene set enrichment analysis was utilized to validate the network-based prediction. **(E)** Top candidates were further prioritized for drug combinations using network-based method captured by the ‘*Complementary Exposure*’ pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network. **(F)** Overall hypothesis of network-based methodology: (i) the proteins that functionally associate with HCoVs are localized in the corresponding subnetwork within the comprehensive human interactome network; and (ii) proteins that serve as drug targets for a specific disease may also be suitable drug targets for potential antiviral infection owing to common protein-protein interactions elucidated by the human interactome.

**Figure 2. Phylogenetic analysis of coronaviruses.** **(A)** Phylogenetic tree of coronavirus (CoV). Phylogenetic algorithm analyzed evolutionary conservation among whole genomes of 15 coronaviruses. Red color highlights the recent emergent

coronavirus, 2019-nCoV, originating in Wuhan, China. Numbers on the branches indicate bootstrap support values. The scale shows the evolutionary distance computed using the p-distance method. **(B)** Schematic plot for HCoV genomes. The genus and host information of viruses was labeled on the left by different colors. Empty dark gray boxes represent accessory open reading frames (ORFs). The 3D structures of SARS-CoV nsp12 (PDB ID: 6NUR) **(C)**, spike (PDB ID: 6ACK) **(D)** and nucleocapsid (PDB ID: 2CJR) **(E)** shown were based on homology modeling. Genome information and phylogenetic analysis results are provided in Supplementary **Table S1-2**.

**Figure 3. Drug-target network analysis of the HCoV-host interactome. (A)**

A subnetwork highlighting the HCoV-host interactome. Nodes represent three types of HCoV-associated host proteins: targetable (proteins can be targeted by approved drugs or drugs under clinical trials), non-targetable (proteins don't have any known ligands), neighbors (protein-protein interaction partners). Edge colors indicate five types of experimental evidences of the protein-protein interactions (see Methods). 3D: three-dimensional structure. **(B)** KEGG human pathway and **(C)** gene ontology enrichment analyses for the HCoV-associated proteins.

**Figure 4. A discovered drug-HCoV network. (A)**

A subnetwork highlighting network-predicted drug-HCoV associations connecting 135 drugs and HCoVs. From the 2,938 drugs evaluated, 135 ones achieved significant proximities between drug targets and the HCoV-associated proteins in the human interactome network. Drugs are colored by


their first-level of the Anatomical Therapeutic Chemical (ATC) classification system code. **(B)** A heatmap highlighting network proximity values for SARS-CoV, MERS-CoV, IBV, and MHV respectively. Color key denotes network proximity (Z-score) between drug targets and the HCoV-associated proteins in the human interactome network. P-value was computed by permutation test.





**Figure 5. A discovered drug-protein-HCoV network for 16 potential repurposable drugs.** **(A)** Network-predicted evidences and gene set enrichment analysis (GSEA) scores for 16 potential repurposable drugs for HCoVs. The overall connectivity of the top drug candidates to the HCoV-associated proteins was examined. Most of these drugs indirectly target HCoV-associated proteins via the human protein-protein interaction networks. All the drug-target-HCoV-associated protein connections were examined, and those proteins with at least 5 connections are shown. The box heights for the proteins indicate the number of connections. GSEA scores for 8 drugs were not available (NA) due to the lack of transcriptome profiles for the drugs. **(B-E)** Inferred mechanism-of-action networks for four selected drugs: **(B)** toremifene (first generation nonsteroidal selective estrogen receptor modulator), **(C)** irbesartan (an angiotensin receptor blocker), **(D)** mercaptopurine (an antimetabolite antineoplastic agent with immunosuppressant properties), and **(E)** melatonin (a biogenic amine for treating circadian rhythm sleep disorders).

**Figure 6. Network-based rational design of drug combinations for HCoV.** (A) The possible exposure mode of the HCoV-associated protein module to the pairwise drug combinations. An effective drug combination will be captured by the ‘*Complementary Exposure*’ pattern: the targets of the drugs both hit the HCoV-host subnetwork, but target separate neighborhoods in the human interactome network.  $Z_{CA}$  and  $Z_{CB}$  denote the network proximity (Z-score) between targets (Drugs A and B) and a specific HCoV.  $S_{AB}$  denotes separation score (see Methods) of targets between Drug A and Drug B. (B-D) Inferred mechanism-of-action networks for three selected pairwise drug combinations: (B) Sirolimus (a potent immunosuppressant with both antifungal and antineoplastic properties) plus Dactinomycin (a RNA synthesis inhibitor for treatment of various tumors), (C) Toremifene (first generation nonsteroidal selective estrogen receptor modulator) plus Emodin (an experimental drug for the treatment of polycystic kidney), and (D) Melatonin (a biogenic amine for treating circadian rhythm sleep disorders) plus Mercaptopurine (an antimetabolite antineoplastic agent with immunosuppressant properties).






**Figure 1**



**Figure 2**


**Figure 3**




**Figure 4**

**A The first-level of ATC code**






- Alimentary tract and metabolism
- Antineoplastic and immunomodulating
- Antiparasitic products
- Blood and blood forming organs
- Cardiovascular system
- Genito-urinary system & sex hormones
- Musculo-skeletal system
- Nervous system
- Respiratory system
- Sensory organs
- Various
- Not available



**B**



**Figure 5**



**Figure 6**

